One panel of European Medicines Agency, shortly called EMA, has come up with a recommendation of “granting marketing approval” towards a drug for diabetes that has been jointly developed by Merck & Co and Pfizer Inc.
The said recommendation of the EMA panel for “Medicinal Products for Human Use” can be a booster to the European Commission bound companies. The drug, an oral treatment used for treating “Type II diabetes”, will be coming to the market under the name of Steglatro.
Steglatro is a “SGLT2 inhibitors” which will help the patients’ “excess glucose” to be expelled “through urine”. While Reuters added:
“In December, Merck and Pfizer won approval from the U.S. Food and Drug Administration for Steglatro as a single therapy and in fixed-dose combinations with Merck’s diabetes drug Januvia or with metformin, an older generic treatment typically given to newly diagnosed patients”.
Diabetes can cause severe organ damage affecting the “eyes and kidneys” besides it can also raise significant risk of “heart attack and stroke”. With the progression of “type II diabetes” many patients require “additional treatments” to keep their “blood sugar levels” under “better control”.
References:
reuters.com
The said recommendation of the EMA panel for “Medicinal Products for Human Use” can be a booster to the European Commission bound companies. The drug, an oral treatment used for treating “Type II diabetes”, will be coming to the market under the name of Steglatro.
Steglatro is a “SGLT2 inhibitors” which will help the patients’ “excess glucose” to be expelled “through urine”. While Reuters added:
“In December, Merck and Pfizer won approval from the U.S. Food and Drug Administration for Steglatro as a single therapy and in fixed-dose combinations with Merck’s diabetes drug Januvia or with metformin, an older generic treatment typically given to newly diagnosed patients”.
Diabetes can cause severe organ damage affecting the “eyes and kidneys” besides it can also raise significant risk of “heart attack and stroke”. With the progression of “type II diabetes” many patients require “additional treatments” to keep their “blood sugar levels” under “better control”.
References:
reuters.com
